SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel Post author: Post published: December 12, 2023 Post category:uncategorized SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. You Might Also Like New approach to understanding chronic inflammation could lead to better cancer therapies December 4, 2024 Whole genome sequencing may guide care for thousands of breast cancer patients October 7, 2025 FarrSight-Twin technology transforms cancer treatment research October 24, 2024
New approach to understanding chronic inflammation could lead to better cancer therapies December 4, 2024